The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The state government on Friday sought to silence doubters to claim that the Drug Reduction Elimination & Action Mission ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...
Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...
For 25 years, 45-year-old Tony Serio was in active addiction. Today, he's successful and has been in recovery for eight years ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback